Gotham__Org Gotham White.png
FACT-ES

Functional Assessment of Cancer Therapy - Endocrine Symptoms

For patients with Endocrine Symptoms

 

Overview

Below are the details for the FACT-ES measure:

MEASURE NAME:

Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)

VERSION:

4

NUMBER OF ITEMS:

46

PATIENT POPULATION:

Cancer patients 18 years and older receiving endocrine treatments

RECALL PERIOD:

Past 7 days

RESPONSE SCALE:

5 point Likert-type scale

DATA COLLECTION:

Paper and electronic

ADMINISTRATION:

Self-administration and interview when applicable

SUBSCALE DOMAINS:

Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Endocrine Symptom Subscale

TIME FOR COMPLETION:

10-15 minutes

SCORING:

Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.

RELATED MEASURES:

Language Availability

Available translations of the FACT-ES can be obtained by registering for permission. Users are not permitted to translate the FACT-ES without permission from FACIT.org. Permission from FACIT.org to translate the FACT-ES may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

 
 

Licensing

Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

 

Selected References

Fallowfield, L. J., Leaity, S. K., Howell, A., Benson, S. & Cella, D.  Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B.  Breast Cancer Research and Treatment 1999; 55: 189-199.  


Fallowfield, L., Atkins, L., Catt, S., Cox, A., Coxon, C., Langridge, C., Morris, R., & Price, M.  Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer.  Annals of Oncology 2006; 17(2): 205–210.  doi: 10.1093/annonc/mdj044. 


Fallowfield, L., Bliss, J., Porter, L., Price, M., Snowdon, C., Jones, S., Coombes, C., & Hall, E. Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer.  Journal of Clinical Oncology 2006; 24(6): 910-917.  doi: 10.1200/JCO.2005.03.3654.


Hickey, M., Marino, J., Braat, S., Wong, S. A randomized, double-blind, crossover trial comparing a silicone versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Research and Treatment 2016; 158:79–90.  doi: 10.1007/s10549-016-3865-1.


Marino, J., Saunders, C., Emery, L., Green, H., Doherty, D., & Hickey, M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014; 21(3): 267-274.  doi: 10.1097/gme.0b013e3182976f46.


Marino J,., Saunders, C., Emery. L., Green, H., Doherty, D., & Hickey, M. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause 2016; 23(9): 1000-1008.  doi: 10.1097/GME.0000000000000664.


Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.


Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.


Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.


Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

 

Related Measures

FACT-B

Functional Assessment of Cancer Therapy – Breast

NFBSI-16

National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Breast Cancer Symptom Index - 16 Item Version

FBSI-8

FACT Breast Symptom Index

Gotham__Group-Gotham-White_SFW.png
Lauren Lent, DHA, MS
President, FACITtrans, LLC
Executive Director, FACIT.org
About Us
© 2020 FACIT.org 
Benjamin Arnold, MA
Executive Director, FACITtrans, LLC
Jason Bredle, MFA
Director, FACIT.org